Health care giant Pfizer (NYSE:PFE) released a press statement Thursday announcing that its drug for major depressive disorder (MDD), Pristiq, successfully hit its endpoints in a phase 4 clinical trial. The drug proved more effective in treating patients as compared to a placebo over an eight-week period.
The FDA originally approved Pristiq for treatment of MDD back in 2008. This latest study lends more credence to the efficacy of the extended-release version of the drug.
"We continue to study PRISTIQ in order to provide clinicians with more information that can better guide their treatment decisions for MDD patients," Dr. Steven J. Romano, senior vice president and head of the Medicines Development Group of Pfizer's Global Primary Care Business Unit, was quoted as saying in the company press release.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.